minute (mean = 68 ml/minute). Protein excretion ranged from 0 to 24-13 g per 24 hours (mean = 3.15 g per 24 hours).
There was a significant inverse correlation of antithrombin III level and urinary protein excretion (r = -0-413, p 2-sided <0-05). Antithrombin III levels were below normal in 5 patients, on at least 1 determination. Four of these patients had a rise in antithrombin III level to normal on serial determinations. In 2 of these patients there was a simultaneous dramatic decrease in urinary protein excretion of at least 6 g of protein per 24 Correspondence 21 1 hours. In the other 2 patients urinary protein excretion did not change during the period that their antithrombin III levels normalised. Both of these patients had clinical and serological evidence of active SLE at the time their antithrombin levels were low. Follow-up samples during disease remission showed normal antithrombin III levels. During the study period thromboembolic disease was not documented in any of the patients.
In conclusion, we have demonstrated that patients with SLE can have an acquired antithrombin III deficiency. There is a significant inverse correlation of antithrombin III level and urinary protein excretion. However, the normalisation of the antithrombin III levels in 2 patients occurred when their SLE became inactive, suggesting that low antithrombin III levels in SLE patients may be related to factors other than urinary protein excretion. Only a long-term prospective study of SLE patients with serial antithrombin III assays will determine if there is a relationship between and acquired antithrombin Ill deficiency and thromboembolic disease in SLE.
Beta-2-microglobulin in RA Sir, In 2 recent studies on serum beta-2-microglobulin (020) in rheumatoid arthritis (RA)1' 2the results are somewhat divergent with regard to the correlation between P4I and the disease activity. We have studied the same subject and would like to report our findings.
Our material consisted of 51 consecutive inpatients with classical RA (ARA criteria 1958). One patient was excluded because ofparaproteinaemia.
The clinical examination showed that the 50 patients could be separated into 2 distinct groups with regard to the disease activity. In 39 patients (mean age 53*8 + 12.0 years, range 25-72 years) no more than a few joints were actually inflamed. Their disease was considered slightly or moderately active. In contrast, 11 patients (mean age 51 + 10.2 years, range 33-63 years) had widespread active arthritis with systemic symptoms such as fever and/or rheumatoid complications (amyloidosis 3, significant Sjogren's syndrome 2, neuropathy 1, necrotising nodules 1). These patients were felt to suffer highly active or complicated rheumatoid disease. The 2 groups were termed groups I and II respectively. P20 was determined by a radioimmunoassay, Phadebas P2-micro test (Pharmacia Diagnostics AB, Uppsala, Sweden).
Serum IgG, IgA, IgM, a1-antitrypsin, orosomucoid, and haptoglobin were analysed by a turbidimetric immunoassay using an Aminco Rotochem II centrifugal fast analyser. Other routine parameters determined were erythrocyte sedimentation rate (ESR), blood lymphocyte count, and serum creatinine.
A quotient was calculated between the obtained P,2t value and the 5,2p value calculated from the linear regression line between P20-and serum creatinine. In both studies RA patients with elevated serum creatinine were omitted and in that of Manicourt et 
